Breyanzi, a CD19-targeted CAR T cell therapy, has received its fourth FDA approval to treat a specific subtype of non-Hodgkin lymphoma.
FDA approves Breyanzi for relapsed or refractory mantle cell lymphoma
Leave a comment
Breyanzi, a CD19-targeted CAR T cell therapy, has received its fourth FDA approval to treat a specific subtype of non-Hodgkin lymphoma.
